Global S&T Development Trend Analysis Platform of Resources and Environment
DOI | 10.1038/s41467-018-07891-7 |
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever | |
Abreu-Mota, Tiago1,2,3; Hagen, Katie R.4; Cooper, Kurt4; Jahrling, Peter B.4,5; Tan, Gene6,7; Wirblich, Christoph1; Johnson, Reed F.5; Schnell, Matthias J.1,8 | |
2019-01-29 | |
发表期刊 | NATURE COMMUNICATIONS
![]() |
ISSN | 2041-1723 |
出版年 | 2018 |
卷号 | 9 |
文章类型 | Article |
语种 | 英语 |
国家 | USA; Portugal |
英文摘要 | Lassa fever (LF), caused by Lassa virus (LASV), is a viral hemorrhagic fever for which no approved vaccine or potent antiviral treatment is available. LF is a WHO priority disease and, together with rabies, a major health burden in West Africa. Here we present the development and characterization of an inactivated recombinant LASV and rabies vaccine candidate (LASSARAB) that expresses a codon-optimized LASV glycoprotein (coGPC) and is adjuvanted by a TLR-4 agonist (GLA-SE). LASSARAB elicits lasting humoral response against LASV and RABV in both mouse and guinea pig models, and it protects both guinea pigs and mice against LF. We also demonstrate a previously unexplored role for non-neutralizing LASV GPC-specific antibodies as a major mechanism of protection by LASSARAB against LF through antibody-dependent cellular functions. Overall, these findings demonstrate an effective inactivated LF vaccine and elucidate a novel humoral correlate of protection for LF. |
领域 | 资源环境 |
收录类别 | SCI-E |
WOS记录号 | WOS:000447075700011 |
WOS关键词 | HUMAN MONOCLONAL-ANTIBODIES ; VESICULAR STOMATITIS-VIRUS ; GUINEA-PIGS ; NEUTRALIZING ANTIBODY ; DERMAL ELECTROPORATION ; MOUSE MODEL ; GLYCOPROTEIN ; INFECTION ; EPIDEMIOLOGY ; EFFICACY |
WOS类目 | Multidisciplinary Sciences |
WOS研究方向 | Science & Technology - Other Topics |
URL | 查看原文 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/204190 |
专题 | 资源环境科学 |
作者单位 | 1.Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; 2.Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal; 3.PT Govt Associate Lab, ICVS 3Bs, P-4710057 Braga, Portugal; 4.NIAID, Integrated Res Facil, NIH, Ft Detrick, MD 21702 USA; 5.NIAID, Emerging Viral Pathogens Sect, NIH, Bethesda, MD 20892 USA; 6.J Craig Venter Inst, Infect Dis, La Jolla, CA 92037 USA; 7.Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA; 8.Thomas Jefferson Univ, Sidney Kimmel Med Coll, Jefferson Vaccine Ctr, Philadelphia, PA 19107 USA |
推荐引用方式 GB/T 7714 | Abreu-Mota, Tiago,Hagen, Katie R.,Cooper, Kurt,et al. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever[J]. NATURE COMMUNICATIONS,2019,9. |
APA | Abreu-Mota, Tiago.,Hagen, Katie R..,Cooper, Kurt.,Jahrling, Peter B..,Tan, Gene.,...&Schnell, Matthias J..(2019).Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.NATURE COMMUNICATIONS,9. |
MLA | Abreu-Mota, Tiago,et al."Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever".NATURE COMMUNICATIONS 9(2019). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论